Related Experiment Videos
Use of interferon for the treatment of chronic hepatitis C in the elderly
C P Eyigun1, D H Van Thiel, N De Maria
1Department of Infectious Diseases, Gulhane Military Medical Academy, Ankara, Turkey.
Insights
Elderly patients with chronic hepatitis C respond well to interferon therapy, showing comparable efficacy and tolerance to younger individuals. This suggests interferon is a viable treatment option for older adults with this condition.
Area of Science:
- Hepatology
- Virology
- Geriatric Medicine
Background:
- Chronic hepatitis C virus (HCV) infection is a global health concern affecting all age groups.
- A significant number of elderly individuals (>65 years) have long-standing HCV infections, with a subset progressing to cirrhosis and hepatocellular carcinoma.
- Interferon is the primary approved therapy for chronic hepatitis C, with established efficacy in younger populations.
Purpose of the Study:
- To assess the efficacy and tolerability of interferon therapy in elderly patients with chronic hepatitis C.
- To compare treatment outcomes in elderly versus younger patient cohorts.
Main Methods:
- Review of existing studies evaluating interferon treatment in elderly patients with chronic hepatitis C.
- Analysis of reported response rates and adverse events in different age groups.
Main Results:
- Elderly patients demonstrated a response rate of 60% to interferon, with 30% achieving a virologic/complete response.
- Interferon was generally well-tolerated in the elderly population.
- No significant differences in tolerability or efficacy were observed between elderly and younger treatment groups.
Conclusions:
- Interferon is an effective and well-tolerated treatment option for chronic hepatitis C in elderly patients.
- The efficacy and safety profile of interferon in the elderly is comparable to that in younger individuals.
- Further research should continue to evaluate treatment strategies for chronic hepatitis C in aging populations.
Abstract:
Hepatitis C virus is a worldwide health care problem. It affects all age groups. Many patients have had the infection for 20-30 years before they present for therapy. With a peak incidence of disease in the 30-40 year age group, it is obvious that a large number of cases must occur in the elderly (age > 65 years). Of these, a fraction progress to cirrhosis and hepatocellular carcinoma. Interferon is the only agent approved for use in patients with chronic hepatitis C. The efficacy of interferon in younger patients is reported to be 50%. Half of these will experience a relapse within 1 year. There are few studies assessing the role of interferon used for elderly patients with chronic hepatitis C. The reported response rate to interferon in elderly patients was 60%, with 30% having a virologic/complete response. These studies demonstrate that the elderly tolerate interferon reasonably well. No significant differences have been reported between elderly and young treatment groups.